Oncology

Adding Trastuzumab to Chemotherapy Improves OS, Review Concludes

December 25th 2018

By Samantha DiGrande

A recent study sought to investigate the overall survival (OS) advantage of the addition of trastuzumab to chemotherapy for patients with human epidermal growth factor 2-positive early breast cancer.

Researchers Report on Clinical Program for Proposed Trastuzumab Biosimilar, HLX02

December 23rd 2018

By The Center for Biosimilars Staff

During the European Society for Medical Oncology’s Asia 2018 annual meeting, held in Singapore from November 23 to November 25, a research team presented an update on the clinical program for HLX02, a proposed trastuzumab biosimilar referencing Herceptin. The proposed biosimilar is being developed by the Chinese firm Shanghai Henlius Biotech.

Beth Wittmer, RN, OCN: How Nurses Are Preparing for Anticancer Biosimilars

December 22nd 2018

Beth Wittmer, RN, OCN, senior manager of care management at Florida Cancer Specialists, addresses how nurses are being educated about biosimilars.

QL1101 Shows Similarity to Reference Bevacizumab in NSCLC in Phase 3 Trial

December 21st 2018

By Kelly Davio

During last month’s European Society for Medical Oncology Asia 2018 annual meeting, held in Singapore from November 23 to November 25, researchers presented data demonstrating the biosimilarity of QL1101 with reference bevacizumab (Avastin).

Mylan and Biocon's Trastuzumab Biosimilar Gains European Marketing Authorization

December 19th 2018

By The Center for Biosimilars Staff

Mylan and Biocon have received final approval from the European Commission to market their trastuzumab biosimilar, Ogivri, referencing Herceptin.

Bevacizumab Biosimilar, IBI305, Meets Primary End Points in 2 Clinical Trials

December 13th 2018

By Kelly Davio

Chinese biologics developer Innovent has announced that its proposed bevacizumab candidate, IBI305, has met its primary end points in 2 randomized, head-to-head clinical trials that compared the biosimilar to the brand-name bevacizumab (Avastin).

United States Still Lags Behind Other Nations in Adopting Biosimilar Filgrastim

December 11th 2018

By Kelly Davio

Since the advent of biosimilar filgrastim, patient access to the prophylaxis of chemotherapy-induced febrile neutropenia has improved in many regulatory territories, yet concerns remain about whether the United States is keeping pace with the rest of the world in biosimilar uptake and associated patient access.

SB3 Shows Comparable Efficacy and Safety to Reference Trastuzumab at 1 Year

December 10th 2018

By Kelly Davio

Samsung Bioepis has announced that a 1-year follow-up study comparing event-free survival in patients treated with SB3, a biosimilar trastuzumab (approved in Europe as Ontruzant) showed that the biosimilar has similar safety and efficacy profiles to the reference Herceptin.

FN Prophylaxis With Biosimilar Filgrastim Generates Substantial Savings Versus Pegfilgrastim On-Body Injector

December 5th 2018

By Samantha DiGrande

There are several options for the prophylaxis of febrile neutropenia (FN), including pegfilgrastim delivered in an on-body injector (OBI), a single injection of pegfilgrastim, and daily injections with reference filgrastim or Sandoz’ biosimilar filgrastim.

Biosimilar Beats Subcutaneous Rituximab on Cost Savings in NHL

December 5th 2018

By Kelly Davio

The launch of biosimilar rituximab is an eagerly awaited event among US healthcare stakeholders who are cognizant of the high cost of intravenously (IV) administered rituximab in treating non-Hodgkin lymphoma (NHL). At the same time, another innovation in rituximab delivery—a subcutaneously administered rituximab formulation—has the potential to save both cost and time.